21 Results for "

renal reabsorption

" in MedChemExpress (MCE) Product Catalog:
Products (21)

21 Results for "renal reabsorption" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-A0080
CAS No.: 94-16-6
Synonyms: Sodium p-aminohippurate; p-Aminohippuric acid sodium salt
Research Areas:  

Inflammation/Immunology

Aminohippurate sodium (Sodium p-aminohippurate) is a renal tubular transport inhibitor and a substrate for organic anion transporters. Aminohippurate sodium inhibits renal tubular reabsorption of phosphate and promotes increased urinary phosphate excretion. Aminohippurate sodium inhibits renal tubular reabsorption of vitamin C as well as the transport of glucose .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W042301
CAS No.: 14293-44-8
Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na +/Cl --potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl -/NaCO3 - anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca 2+ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9939
CAS No.: 1610833-03-8
Synonyms: KRN23; N5KG1_C10_LH; UX-023

Target:  

Inhibitory Antibodies

Research Areas:  

Metabolic Disease Cancer

Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109018B
CAS No.: 1661838-94-3
Purity:  99.43%
Target:  

SGLT

Research Areas:  

Metabolic Disease

Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109018A
CAS No.: 1539295-26-5
Purity:  99.43%
Target:  

SGLT

Research Areas:  

Metabolic Disease

Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
loading...
    loading...
Cat. No.: HY-156696
CAS No.: 215183-03-2
Research Areas:  

Metabolic Disease

S3226 is a highly selective NHE-3 inhibitor (IC50<1 μM) that specifically blocks NHE-3-mediated sodium transport. S3226 significantly inhibits blastocyst formation and expansion in mouse embryos, and reduces fluid and electrolyte reabsorption in rat proximal tubules in a dose-dependent manner. S3226 effectively alleviates ischemia-induced acute renal failure by improving renal function parameters, reducing renal tubular injury and restoring intracellular pH homeostasis, without interfering with the normal tubuloglomerular feedback response. S3226 is widely used in studies of acute renal failure and related pathological mechanisms .
loading...
    loading...
Cat. No.: HY-N0394R
CAS No.: 56-89-3
L-Cystine (Standard) is the analytical standard of L-Cystine. This product is intended for research and analytical applications. L-Cystine, the extracellular form of L-Cysteine (HY-Y0337), is a nutritionally dispensable semiessential sulfur-containing amino acid, occurring in proteins of plants and animals. L-Cystine induces Nrf2 protein elevation in a Keap1 (HY-P75897)-dependent manner and activates Nrf2 transcription factor. L-cystine can elicit cytoprotection by reducing ROS generation and protecting against oxidant- or doxorubicin-induced apoptosis. The reduced reabsorption of L-Cystine in renal tubules and its poor solubility in urine are the important causes of cystine precipitation and cystine crystal formation eventually leading to kidney stones. L-Cystine combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine is promising for research of cystinuria and cystinosis
loading...
    loading...
Cat. No.: HY-109542
CAS No.: 742-20-1
Purity:  98.40%
Research Areas:  

Metabolic Disease

Cyclopenthiazide is a benzothiadiazine diuretic with antihypertensive properties. Cyclopenthiazide exerts a diuretic effect by inhibiting the reabsorption of sodium chloride and water at the distal renal tubules. Cyclopenthiazide increases the excretory capacity of the rat kidney .
loading...
    loading...
Cat. No.: HY-13414
CAS No.: 329045-45-6
Synonyms: Remogliflozin A
Target:  

SGLT

Research Areas:  

Metabolic Disease

Remogliflozin (Remogliflozin A) is an orally active, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, with a Ki of 12.4 nM for human SGLT2 and 26.0 nM for rat SGLT2. Remogliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption. Without insulin stimulation, remogliflozin suppresses the elevation of plasma glucose, reduces fasting blood glucose and glycated hemoglobin, and improves glycosuria, hyperglycemia, hyperinsulinemia, hypertriglyceridemia and insulin resistance in diabetic rodents. Remogliflozin can be used in research related to type 2 diabetes .
loading...
    loading...
Cat. No.: HY-179107
CAS No.: 3104477-57-5
Research Areas:  

Metabolic Disease

SLC6A19-IN-3 (Compound 83-P1-P2) is a potent, selective and orally active SLC6A19 inhibitor with an IC50 of 28 nM. SLC6A19-IN-3 can block SLC6A19-mediated transmembrane transport of phenylalanine, reducing intestinal absorption of phenylalanine from food and renal tubular reabsorption of phenylalanine. SLC6A19-IN-3 can be used for the research of metabolic disease, such as phenylketonuria .
loading...
    loading...
Cat. No.: HY-106300
CAS No.: 107804-48-8
AA 193 is an orally active uricosuric agent. AA 193 inhibits the net reabsorption of uric acid in nephrons, regulates the renal reabsorption process of filtered uric acid, promotes uric acid excretion in a dose-dependent manner, and reduces serum uric acid levels. AA 193 mildly inhibits the activity of xanthine dehydrogenase (XDH). AA 193 can be used in studies related to hyperuricemia .
loading...
    loading...
Cat. No.: HY-120147
CAS No.: 1824-58-4
Ethiazide is a thiazole diuretic which inhibits renal reabsorption of sodium and water, thereby increasing urine excretion, reducing fluid retention, and lowering blood volume and blood pressure. Ethiazide can be used for cardiovascular research .
loading...
    loading...
Cat. No.: HY-109542R
CAS No.: 742-20-1
Cyclopenthiazide (Standard) is the analytical standard of Cyclopenthiazide. This product is intended for research and analytical applications. Cyclopenthiazide is a benzothiadiazine diuretic with antihypertensive properties. Cyclopenthiazide exerts a diuretic effect by inhibiting the reabsorption of sodium chloride and water at the distal renal tubules. Cyclopenthiazide increases the excretory capacity of the rat kidney .
loading...
    loading...
Cat. No.: HY-165423
CAS No.: 926035-36-1
DM-4111, one of the major monohydroxyl metabolites of Tolvaptan (HY-17000), is a potent vasopressin V2 receptor inhibitor. DM-4111 inhibits water reabsorption in the renal tubules, thereby promoting the excretion of electrolyte-free water. DM-4111 is promising for research of cardiovascular diseases .
loading...
    loading...
Cat. No.: HY-109018AR
CAS No.: 1539295-26-5
Research Areas:  

Metabolic Disease

Velagliflozin proline (Standard) is the analytical standard of Velagliflozin (proline) (HY-109018A). This product is intended for research and analytical applications. Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
loading...
    loading...
Cat. No.: HY-109018BR
CAS No.: 1661838-94-3
Research Areas:  

Metabolic Disease

Velagliflozin proline hydrate (Standard) is the analytical standard of Velagliflozin (proline hydrate) (HY-109018B). This product is intended for research and analytical applications. Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
loading...
    loading...
Cat. No.: HY-178734
CAS No.: 1800115-22-3
Target:  

SGLT

Research Areas:  

Metabolic Disease

Janagliflozin is orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50=0.0058 μM for SGLT2 and 4.802 μM for SGLT1). Janagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion (UGE) to lower blood glucose levels. Janagliflozin is promising for research of type 2 diabetes mellitus .
loading...
    loading...
Cat. No.: HY-189427
CAS No.: 3129164-13-9
Research Areas:  

Metabolic Disease

URAT1-IN-17 is an orally active URAT1 inhibitor with an IC50 of 5.32 μM in HEK293T cells. URAT1-IN-17 inhibits URAT1-mediated uric acid reabsorption in the renal proximal tubule, thereby reducing serum uric acid levels. URAT1-IN-17 weakly inhibits OAT1-mediated organic anion transport. URAT1-IN-17 can be used for research on hyperuricemia .
loading...
    loading...
Cat. No.: HY-Y0282
CAS No.: 7647-15-6
Synonyms: NSC 77384; Sanibrom 40
Research Areas:  

Neurological Disease

Sodium bromide (NSC 77384; Sanibrom 40) is a GABA-ergic system modulator that crosses the blood-brain barrier, and it effectively reduces and blocks epileptiform discharges. Sodium bromide exerts significant anticonvulsant effects by enhancing GABA-ergic inhibitory functions, such as increasing the amplitude of inhibitory postsynaptic currents and paired-pulse inhibition. Sodium bromide specifically enhances stimulation-induced extracellular alkalosis without affecting baseline pH or subsequent acidosis processes. Sodium bromide exhibits species-specific pharmacokinetic characteristics, competes with chloride ions for renal tubular reabsorption sites, and serves as a marker for extracellular fluid volume. Sodium bromide can be used in the research of epilepsy and related neurological diseases .
loading...
    loading...
Cat. No.: HY-W343043
CAS No.: 60398-24-5
Synonyms: PZG
Target:  

Drug Derivative

Pyrazinoylguanidine (PZG) is an analogue of the potassium sparing diuretic, Amiloride (HY-B0285). Pyrazinoylguanidine can lower the systolic and diastolic blood pressure of patients with primary hypertension, has a certain effect on reducing heart rate, and does not affect the concentrations of electrolytes such as sodium, potassium, and chloride in the blood serum. Pyrazinoylguanidine can reduce the hyperglycemia and hyperinsulinemia in type 2 diabetes, reduce the levels of triglycerides, cholesterol, and free fatty acids, and reverse the hyperglycemia and hyperlipidemia induced by thiazide diuretics, such as Hydrochlorothiazide (HY-B0252). Pyrazinoylguanidine ican nhibit the reabsorption of urea by the renal tubules, thereby increasing the clearance rate and excretion volume of urea, reducing the serum urea concentration, and minimizing its toxic accumulation .
loading...
    loading...